Avalo Therapeutics reports Phase 2 success in inflammatory skin disorder and secures $375M financing
read at Endpoints ↗Positive readoutPositive
Avalo Therapeutics announced on May 6, 2026 that its experimental immunology drug met its primary endpoints in a Phase 2 study of an inflammatory skin condition.
The trial tested two dose levels, and both showed the expected clinical activity, giving the company confidence to advance the program.
In the same announcement, Avalo disclosed a $375 million financing round intended to fund further development and support its turnaround plan.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Avalo scores Phase 2 success in comeback bid, raises $375M”
read at Endpoints ↗81 words · retrieved May 6
comments(0)
5-min edit window · permanent after that